Systemic Sarcoidosis Management

Clinical Presentation

• Systemic sarcoidosis presents with diverse manifestations affecting multiple organ systems, with lungs and intrathoracic lymph nodes involved in over 90% of cases, while treatment decisions should be based on risk of mortality, permanent disability, and quality of life impact 1
• Cardiac involvement can lead to significant mortality 2
• New-onset third-degree AV block in young or middle-aged adults is highly suggestive 3
• Central nervous system involvement can cause significant morbidity 2
• Eye involvement is a common extrapulmonary manifestation 2
• Hypercalcemia or hypercalciuria with abnormal vitamin D metabolism can occur 3
• Hepatosplenomegaly can be present 3
• Renal involvement with potential for treatment-responsive renal failure can occur 3

Treatment Approach

• Treatment is indicated for risk of death/permanent disability or to improve quality of life 4, 1
• Less than 10% of patients die from sarcoidosis, mostly from advanced lung disease 4
• Recurrence of disease is common if treatment is withdrawn too soon 4
• At least 25% of patients require treatment for more than 2 years 4
• TNF inhibitors (infliximab, adalimumab) can be used for refractory cases, particularly for small-fiber neuropathy 4, 5
• Intravenous immunoglobulin (IVIg) may be considered for persistent small-fiber neuropathy symptoms 4, 5

Treatment for Specific Manifestations

• For mild/non-disabling small-fiber neuropathy symptoms: consider topiramate, tramadol, α-lipoic acid, or topical therapies (lidocaine, capsaicin) 4
• For severe/disabling small-fiber neuropathy symptoms: GABA analogues or antidepressants 4
• For persistent small-fiber neuropathy symptoms despite first-line treatment: consider IVIg or TNF inhibitors 4

Treatment Duration and Monitoring

• Relapse rates of 20-80% have been reported upon glucocorticoid withdrawal after 2 years 2
• Withdrawal of methotrexate after 2 additional years was associated with 80% re-institution of systemic therapy 2
• Discontinuation of infliximab after 6-12 months was associated with relapse in more than half of cases 2

Special Considerations

• Treatment decisions should be individualized based on organ involvement, disease severity, and impact on quality of life 1
• Careful assessment of all potential organ involvement is essential as sarcoidosis can affect multiple systems simultaneously 4

Initial Treatment Approach for Sarcoidosis

Decision to Treat

• The European Respiratory Society recommends that treatment decisions be based on the risk of death or permanent organ damage and the impact on quality of life 6
• Symptomatic disease, such as cough, dyspnea, and constitutional symptoms, is an indication for treatment, according to the European Respiratory Review 7

Initial Corticosteroid Therapy

• The initial dose of oral prednisone should be 20-40 mg daily, as recommended by the European Respiratory Review 7
• Dose adjustments are required for patients with diabetes, psychosis, or osteoporosis, according to the European Respiratory Review 7

Monitoring Response

• The European Respiratory Journal recommends follow-up intervals of 3-6 months after initiation of treatment to assess for symptom improvement 6
• Inhaled corticosteroids should only be used for symptomatic relief of cough and asthma-like symptoms, and discontinued if ineffective, as stated in the European Respiratory Review 7

Management Based on Disease Response

• The European Respiratory Review recommends decreasing the steroid dose to the lowest effective dose that provides symptom relief and disease control if improvement occurs 7
• For stable disease, the steroid dose should be decreased to minimize long-term side effects, according to the European Respiratory Review 7
• For worsening disease, adjunctive therapy should be added, and the diagnosis should be re-evaluated, as recommended by the European Respiratory Review 7

Steroid-Sparing Alternatives

• The European Respiratory Review recommends considering steroid-sparing alternatives in scenarios such as high risk for steroid toxicity, inadequate response to steroid therapy, or expectation of prolonged and/or high-dose steroid therapy 7
• Methotrexate is the preferred initial non-biologic therapy, according to the European Respiratory Review 7

Common Pitfalls and Caveats

• Prolonged corticosteroid use is associated with significant toxicity, as stated in the European Respiratory Journal 6

Sarcoidosis Treatment with Multi-Organ Involvement

Initial Therapy and Monitoring

• The European Respiratory Society recommends oral prednisone at 20-40 mg daily as first-line treatment for symptomatic multi-organ sarcoidosis, effective for controlling both pulmonary and hepatic manifestations of sarcoidosis 8
• Treatment is indicated due to evidence of pulmonary involvement (ILD) 8

Steroid-Sparing Considerations

• The European Respiratory Review suggests considering early addition of steroid-sparing agents if there is an inadequate response to initial steroid therapy 9
• Methotrexate is the preferred first-line steroid-sparing agent, with recent evidence showing it may be as effective as prednisone with a different side effect profile 9

Special Considerations for Hepatic and Pulmonary Involvement

• Azathioprine is considered for hepatic and pulmonary involvement 10
• Mycophenolate is considered for ILD, with glucocorticoids conditionally recommended as first-line treatment for SARD-ILD (including sarcoidosis-related ILD) 11
• The American College of Rheumatology recommends monitoring liver function tests regularly during treatment, with consideration of ursodeoxycholic acid as adjunctive therapy for cholestatic features 10

Management of Sarcoidosis Based on Clinical Parameters

Diagnosis and Treatment Considerations

• Low or normal ACE levels do not exclude active sarcoidosis requiring treatment, according to the European Respiratory Society, treatment decisions should be based on clinical symptoms, organ involvement risk, and quality of life impact—not ACE levels alone 12
• Serum ACE has limited sensitivity and specificity as a diagnostic marker, and its absence does not rule out significant disease, as stated by the European Respiratory Society and Rhinology guidelines 13

Monitoring and Treatment Adjustments

• The European Respiratory Journal recommends not delaying treatment while waiting for ACE normalization—treat based on clinical, functional, and radiographic parameters 12
• Rhinology guidelines suggest using alternative markers for disease activity assessment, such as serum soluble IL-2 receptor and lysozyme, as alternative biomarkers 13